Druggability & Clinical Context
Druggability
Medium
Score: 0.64
Druggability Analysis
Structural Tractability0.95
Key Metrics
PDB Structures:
62
Known Drugs:
3
Approved:
3
In Clinical Trials:
0
Drug Pipeline (3 compounds)
3 Approved
Therapeutic Areas:Type 2 diabetes Obesity/weight management Alzheimer's disease Parkinson's disease Neurodegeneration Neuroprotection Neurodegenerative disorders
Druggability Rationale: GLP1R is highly druggable due to its well-characterized Class B GPCR architecture with 62 available PDB structures at sub-2Å resolution, extensive precedent from three approved agonists (semaglutide, liraglutide, exenatide) with established safety profiles, and a confirmed high druggability score of 0.80. The combination of multiple structural templates, known chemical matter, and demonstrated clinical efficacy across diabetes and obesity indications strongly supports rational drug design for neurodegeneration applications.
Mechanism: GLP-1 receptor agonist peptides and small molecule modulators
Drug Pipeline (3 compounds)
3 Approved
Known Drugs:Semaglutide (approved) — Diabetes, obesity
Liraglutide (approved) — Diabetes
Exenatide (approved) — Diabetes
Structural Data:PDB (62) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:The GLP1R binding pocket accommodates both peptide agonists and small molecule modulators, with the orthosteric site formed by transmembrane helices 2-7 and extracellular loops, as detailed in high-resolution structures (best resolution 1.8Å). Cryo-EM and AlphaFold modeling reveal allosteric modulation sites and G-protein coupling interfaces critical for biased signaling, enabling structure-based optimization of neuroprotective pathway selectivity.
Selectivity & Safety Considerations
GLP1R selectivity can be challenging due to structural homology with other Class B GPCRs (GCG, GIP, GCN receptors); however, approved agonists demonstrate adequate selectivity in clinical use. Off-target activation of related incretin receptors may produce undesired gastrointestinal or metabolic effects, requiring careful pharmacophore optimization for CNS-penetrant candidates targeting neurodegeneration.
Clinical Trials (8)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 2 · PHASE2: 2 · PHASE3: 3 · PHASE4: 1
PHASE3
NCT07150975
n=420
Obesity/Overweight in Adult
Interventions: GZR18, Semaglutide(Wegovy® )
Sponsor: Gan & Lee Pharmaceuticals. | Started: 2025-09-23
PHASE2
NCT07227948
n=75
Cocaine Use Disorder
Interventions: Semaglutide, Placebo, cognitive behavioral therapy (CBT).
Sponsor: The University of Texas Health Science Center, Houston | Started: 2026-01-15
NA
NCT06487832
n=60
Normal Weight, Overweight and Obesity, Insulin Sensitivity
Interventions: Subcutaneous GLP1-RA, Subcutaneous placebo
Sponsor: University Hospital Tuebingen | Started: 2024-07-01
PHASE4
NCT07073053
n=60
Glucagon-Like Peptide-1 Receptor Agonist, Type 2 Diabetes, Coronary Arterial Disease (CAD)
Interventions: Semaglutide 1.0 mg, Semaglutide 0.5 mg
Sponsor: Taipei Veterans General Hospital, Taiwan | Started: 2025-10-01
PHASE3
NCT07282613
n=80
Diabetes Mellitus, Type 2
Interventions: CagriSema (Cagrilintide B and Semaglutid, Placebo matched to CagriSema (Cagrilinti
Sponsor: Novo Nordisk A/S | Started: 2026-08-04
PHASE2
NCT07135245
n=180
Alzheimer Disease (AD)
Interventions: Semaglutide (Rybelsus®) combined with ot, Placebo, Semaglutide (Rybelsus®)
Sponsor: Rune Skovgaard Rasmussen | Started: 2026-01-01
NA
NCT06546384
n=64
Adiposity, Fatty Liver, Alcohol Use Disorder
Interventions: Semaglutide, Weight reduction recommendations (nutrit
Sponsor: Insel Gruppe AG, University Hospital Bern | Started: 2026-05-01
PHASE3
NCT04520490
n=63
Childhood Obesity
Interventions: Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo
Sponsor: Seattle Children's Hospital | Started: 2021-01-28